1. Metoprolol use is associated with improved outcomes in patients with sepsis-induced cardiomyopathy: an analysis of the MIMIC-IV database.
- Author
-
Zhong L, Zhong Y, Liao Y, and Zhou Y
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Treatment Outcome, Time Factors, Risk Factors, Risk Assessment, Retrospective Studies, Metoprolol therapeutic use, Metoprolol adverse effects, Sepsis mortality, Sepsis drug therapy, Sepsis diagnosis, Sepsis complications, Hospital Mortality, Databases, Factual, Cardiomyopathies mortality, Cardiomyopathies drug therapy, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Adrenergic beta-1 Receptor Antagonists therapeutic use, Adrenergic beta-1 Receptor Antagonists adverse effects
- Abstract
Background: Metoprolol is commonly administered to critically ill patients; however, its effect on mortality in patients with sepsis-induced cardiomyopathy (SICM) remains uncertain. This study aimed to investigate the relationship between metoprolol use and mortality in patients with SICM., Methods: Adults with SICM were identified from the MIMIC-IV database. The exposure of interest was metoprolol treatment. The outcomes assessed were 30-day mortality, 1-year mortality, and in-hospital mortality. Kaplan-Meier survival analysis evaluated the effect of metoprolol on these outcomes. Multivariable Cox proportional hazards and logistic regression analyses were performed to determine the correlation between metoprolol treatment and mortality in patients with SICM., Results: 1163 patients with SICM were identified, with 882 receiving metoprolol treatment (MET group) and 281 not receiving metoprolol treatment (NOMET group). Overall, the 30-day, 1-year, and in-hospital mortality rates were 10.2%, 18.2%, and 8.9%, respectively. Significant differences in mortality existed between the groups. Multivariable Cox analysis revealed that patients in the NOMET group had a higher risk of 1-year mortality (adjusted hazard ratio [HR] 2.493; 95% confidence interval [CI] 1.800-3.451; P < 0.001) and 30-day mortality (adjusted HR 4.280; 95%CI 2.760-6.637; P < 0.001). Metoprolol treatment was associated with lower in-hospital mortality (odds ratio [OR] 5.076; 95% CI 2.848-9.047; P < 0.001). Subgroup analysis supported these findings., Conclusion: Metoprolol treatment is associated with reduced all-cause mortality in patients with SICM. Prospective studies are required to validate these findings., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF